Leap Therapeutics (LPTX)
(Delayed Data from NSDQ)
$2.20 USD
+0.03 (1.38%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.19 -0.01 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LPTX 2.20 +0.03(1.38%)
Will LPTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LPTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LPTX
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
LPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA
Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint
Other News for LPTX
Leap Therapeutics initiated with bullish view at Rodman & Renshaw
Buy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid Financials
Buy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic Expansion
Leap Therapeutics price target lowered by $1.50 at H.C. Wainwright, here's why
LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024